Business, energy, technology, markets and global industry news from Business News Today

Vyvgart

PharmaDeviceNews Vyvgart
A molecular illustration of antibody activity highlights argenx SE’s $2.2 billion acquisition of Forte Biosciences and the addition of investigational anti-CD122 antibody FB102 to its immunology pipeline. Representative image.
Pharma & Biotech

argenx Forte Biosciences acquisition: What the $2.2bn FB102 deal means for immunology

argenx is buying Forte Biosciences for $2.2bn to secure FB102. See why early vitiligo and celiac data make Phase 2 execution decisive.

Read More
Zai Lab prepares to report second-quarter 2026 results as investors assess revenue recovery, new China product launches and progress across its oncology and neuroscience pipeline. Representative image.
Pharma & Biotech

Zai Lab’s August 6 earnings could reveal whether its 2026 commercial reset is starting to work

Zai Lab reports Q2 2026 results on August 6 as investors assess revenue pressure, COBENFY and TIVDAK launches, and zoci pipeline progress.

Read More
Representative image: A clinician discusses neuromuscular treatment options with an adult patient as Argenx SE’s expanded Vyvgart approval broadens the FDA label across all adult generalized myasthenia gravis serotypes, strengthening interest in targeted FcRn therapies for autoimmune neurology.
Pharma & Biotech

Why Argenx’s broader Vyvgart label changes the treatment equation in generalized myasthenia gravis

Vyvgart now covers all adult gMG serotypes. Argenx gains a wider label, but payers and real-world durability remain the next test.

Read More